PRECIGEN, INC. Non Peo Neo Avg Total Comp Amt
PRECIGEN, INC. (PGEN) reported Non Peo Neo Avg Total Comp Amt of $1.43 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-30.
Financial Statements › Notes
ecd:NonPeoNeoAvgTotalCompAmt · last filed 2026-04-30
| Period end | Non Peo Neo Avg Total Comp Amt 12 month |
|---|---|
| 2025-12-31 | $1.43M DEF 14A · filed 2026-04-30 |
| 2024-12-31 | $1.31M DEF 14A · filed 2026-04-30 |
| 2023-12-31 | $1.03M DEF 14A · filed 2026-04-30 |
| 2022-12-31 | $892.36K DEF 14A · filed 2026-04-30 |
| 2021-12-31 | $611.02K DEF 14A · filed 2026-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |